Fig. 1From: Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort studyRituximab retention rate. Kaplan–Meier curve showing the retention probability of rituximab treatment by indication with 95% CIBack to article page